title: Does long-term aspirin use have any effect on Helicobacter pylori eradication?
abstract: BACKGROUND
  Antimicrobial resistance has decreased eradication rates for Helicobacter pylori infection, and recent reports from different countries report eradication rates lower than 80% with triple therapy. The aim of this pilot study was to investigate the efficacy of standard triple eradication regimen in long-term aspirin users.
  
  
  METHODS
  The study population consisted of 77 aspirin using patients with dyspeptic symptoms and 79 age- and sex-matched dyspeptic patients without aspirin use as a control group. Both the study group and control patients were given lansoprazole (30 mg twice a day), clarithromycin (500 mg twice a day) and amoxicillin (1 g twice a day) (LCA) for 14 days as the eradication regimen. Patients on the study group were allowed to take aspirin during the eradication regimen (LCAAsp). Eradication was defined as the absence of H pylori as assessed with the C-urea breath test and H pylori stool antigen test 8 weeks after the end of the antimicrobial therapy.
  
  
  RESULTS
  The H pylori eradication rate in the LCAAsp group was 64/77 [83%, 95% confidence interval (CI): 79%-94%] with intention-to-treat (ITT) analysis and 64/75 (85%, 95% CI: 82%-96%) with per protocol (PP) analysis, and the H pylori eradication rate in the LCA group was 42/79 (53%, 95% CI: 43%-65%) with ITT analysis and 42/75 (56%, 95% CI: 46%-68%) with PP analysis. The difference between the groups both with ITT analysis and with PP analysis was statistically significant (P < 0.05).
  
  
  CONCLUSIONS
  These data suggest that H pylori eradication rate with standard triple eradication regimen is significantly higher among long-term aspirin users than in controls.
authors.affiliation: Department of Gastroenterology, Baskent University Faculty of Medicine, Konya, Turkey. savasgokturk@yahoo.com
authors.forename: Huseyin Savas
authors.initials: HS
authors.lastname: Gokturk
authors.forename: Mehmet
authors.initials: M
authors.lastname: Demir
authors.forename: Gulhan Kanat
authors.initials: GK
authors.lastname: Unler
authors.forename: Mustafa
authors.initials: M
authors.lastname: Erbayrak
authors.forename: Murat
authors.initials: M
authors.lastname: Sakalli
authors.forename: Ugur
authors.initials: U
authors.lastname: Yilmaz
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage; D000658:Amoxicillin / Q000008:administration & dosage; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D001241:Aspirin / Q000627:therapeutic use*; D016022:Case-Control Studies; D017291:Clarithromycin / Q000008:administration & dosage; D004352:Drug Resistance, Microbial; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000517:prevention & control; D016480:Helicobacter pylori / Q000378:metabolism*; D006801:Humans; D064747:Lansoprazole; D008297:Male; D010865:Pilot Projects; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D001241:Aspirin